Skip to main content
Premium Trial:

Request an Annual Quote

Berg Partners With Sanofi on Flu Biomarker Research

NEW YORK (GenomeWeb) – Biotech firm Berg announced today that it has partnered with Sanofi to identify biomarkers of influenza vaccine performance.

Under the terms of the deal, Berg will use its Interrogative Biology platform — which uses the company's artificial intelligence technology to analyze molecular and clinical data — in order to assess potential biomarkers of seasonal influenza vaccination outcomes in an unbiased and data-driven manner.

Additional terms were not disclosed.

"Interrogative Biology includes multi-omic profiling of samples from individuals participating in a longitudinal study with Sanofi Pasteur-licensed vaccines and subsequent use of our bAIcis artificial intelligence tool with the aim to identify molecular signatures and potential biomarkers indicative of breadth and durability of the influenza vaccine immunological response," Berg Cofounder, President, and CEO Niven Narain said in a statement.

The Scan

Call for a Different Tack

Experts weigh the value of recent experiments testing genetically modified pig kidneys using brain-dead individuals, according to Nature News.

Wastewater Warning

The New York Times reports that wastewater surveillance in some parts of the US point to a possible surge.

Can't Get in the Program

Due to the Northern Ireland protocol dispute, the European Union is preventing UK researchers from joining the Horizon Europe research program, the Times of London reports.

Science Paper on Spatial-Controlled Genome Editing

In Science this week: approach to enable a CRISPR-Cas13a-based system to be used as a cancer therapy.